Precision of CVwr in replicate designs [General Statistics]
Dear Helmut,
The 50% is only valid if you talk EMA .
Otherwise all the data are used for the fit of a (mixed) model.
Why not use the confidence intervals of the covariance parameter estimates from the fit of a mixed model as precision? Ok, this leaves out the partial replicate design because we are not aware if the σ2WR is valid from fitting the mixed model, at least in the form of FDA code.
At least we can think in terms of intra-subject contrasts to estimate σ2WR via an ANOVA with sequence group as the solely effect (as implemented in the FDA progesterone guidance in the framework of scaled ABE). The df for this analysis are n-seq where n is the number of intra-subject contrasts evaluable (=subject/2 in case of design TRT|RTR i.e. the 50% above are again correct).
Thus take formulas given by your own in the early days of this forum for obtaining a confidence interval for σ2WR and then transformed to CV to obtain a measure of the precision of estimated CVWR.
Lets go with the numbers of subjects given by you and assume that the estimated CV is obtained always as 20% (statistically only with vanishing probability ):
gives
BTW: May it be that there is an error in this post in calculating
❝ I’m wondering what we can say about the precision of estimated CVWR in different replicate designs. [...] Let’s look from how many subjects the value is estimated:
❝ TRTR|RTRT: 20 (100%)
❝ TRR|RTR|RRT: 30 (100%)
❝ TRT|RTR: 15 (50%)
❝ Heretic question: From TRT|RTR the estimate will be less precise (only half of the subjects used) ...
The 50% is only valid if you talk EMA .
Otherwise all the data are used for the fit of a (mixed) model.
Why not use the confidence intervals of the covariance parameter estimates from the fit of a mixed model as precision? Ok, this leaves out the partial replicate design because we are not aware if the σ2WR is valid from fitting the mixed model, at least in the form of FDA code.
At least we can think in terms of intra-subject contrasts to estimate σ2WR via an ANOVA with sequence group as the solely effect (as implemented in the FDA progesterone guidance in the framework of scaled ABE). The df for this analysis are n-seq where n is the number of intra-subject contrasts evaluable (=subject/2 in case of design TRT|RTR i.e. the 50% above are again correct).
Thus take formulas given by your own in the early days of this forum for obtaining a confidence interval for σ2WR and then transformed to CV to obtain a measure of the precision of estimated CVWR.
Lets go with the numbers of subjects given by you and assume that the estimated CV is obtained always as 20% (statistically only with vanishing probability ):
# R function upper confidence limit of CV - as one liner
CVUCL <- function(alpha=0.05, CV, df){
sqrt(exp(log(1.0 + CV^2)*df/qchisq(alpha,df))-1)
}
gives
design n df upper CL
TRTR|RTRT 20 18 27.94%
TRR|RTR|RRT 30 27 26.03%
TRT|RTR 15 13 30.07%
BTW: May it be that there is an error in this post in calculating
SS-intra
from MS-intra
? The final result is again correct . That remains me on my old school days: Bad school grade (5) if final result correct but intermediate steps with errors .—
Regards,
Detlew
Regards,
Detlew
Complete thread:
- Precision of CVwr in replicate designs Helmut 2012-10-11 17:29 [General Statistics]
- Precision of CVwr in replicate designs jag009 2012-10-12 16:52
- Tóthfalusi et al. (2009) Helmut 2012-10-12 17:37
- Precision of CVwr in replicate designsd_labes 2012-10-17 10:40
- Great post! Helmut 2012-10-17 15:28
- Nice to know? d_labes 2012-10-17 16:39
- Nice to know! Helmut 2012-10-17 19:11
- Nice to know? d_labes 2012-10-17 16:39
- Great post! Helmut 2012-10-17 15:28
- Precision of CVwr in replicate designs jag009 2012-10-12 16:52